CoreMap Completes $10.5 Million Series A Financing

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

September 16, 2020

CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such as Ronny Ginor, MD of Fifth Focus/HRMG Investments and Orbimed Venture Partners, and a diverse group of new strategic, corporate and financial partners.

The company was founded in 2016 by Dr. Peter Spector and based on his groundbreaking work concerning the drivers of Atrial Fibrillation. Dr. Ginor, an Advisor and investor in the Company said, “CoreMap’s inventions have broad potential for biological sensing which in turn may unlock patient-specific treatment for the millions of people suffering with persistent AF issues.”

CoreMap notes the funds will be used to accelerate the Company’s ongoing product development and their planned regulatory submission of the Company’s first products. These products will be targeted at improving diagnostic capabilities for complex cardiac arrhythmias. Allen Kamer, a founding partner of Qure Ventures, and Dr. Ginor will join the Board of Directors. Additionally, Dr. Spector will become the Chair of the Company’s Scientific and Clinical Advisory Board.

CoreMap is developing a diagnostic technology capable of identifying the drivers of complex arrhythmias, which promises to enable new treatment options for the 33 million patients suffering from AF. At the heart of CoreMap’s technology is a patented electrode pair design in a high-density array configuration combined with algorithm driven mapping and visualization software that will enable electrophysiologists to make more informed therapeutic decisions and improve patient outcomes.

“CoreMap has developed a promising new technology which has vast potential to improve treatment for millions of patients with Atrial Fibrillation,” said Allen Kamer, Managing Partner of Qure. “CoreMap has a unique solution to a growing problem for millions of patients with limited treatment options. Qure is excited to join this talented and driven team on their mission to improve patient outcomes.”

“We are building a group of smart, hardworking, innovative, people committed to delivering a cure for AF,” said CoreMap CEO and Co-Founder, Sarah Kalil. “Having the financial support and domain expertise of the health tech pioneers that are resident in our investor group will allow us to better execute on our vision and change lives.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.